@article{7853b22428d841c1bae89358d2216a3d,
title = "Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey",
abstract = "Background: European Society for Medical Oncology Women for Oncology (ESMO W4O) research has previously shown under-representation of female oncologists in leadership roles. As early reports suggested disproportionate effects of the COVID-19 pandemic on women, the ESMO W4O Committee initiated a study on the impact of the pandemic on the lives of female and male oncologists. Methods: A questionnaire was sent to ESMO members and put on the ESMO website between 8 June 2020 and 2 July 2020. Questions focused on the working (hospital tasks, laboratory tasks, science) and home (household management, childcare, parent care, personal care) lives of oncologists during and after COVID-19-related lockdowns. Results: Of 649 respondents, 541 completed the questionnaire. Of these, 58% reported that COVID-19 had affected their professional career, 83% of whom said this was in a negative way (85% of women versus 76% of men). Approximately 86% reported that COVID-19 had changed their personal life and 82% their family life. Women were again significantly more affected than men: personal life (89% versus 78%; P = 0.001); family life (84% versus 77%; P = 0.037). During lockdowns, women reported increased time spent on hospital and laboratory tasks compared with men (53% versus 46% and 33% versus 26%, respectively) and a significantly higher proportion of women than men spent less time on science (39% versus 25%) and personal care (58% versus 39%). After confinement, this trend remained for science (42% versus 23%) and personal care (55% versus 36%). Conclusions: The COVID-19 pandemic has adversely affected the professional and home lives of oncologists, especially women. Reduced research time for female oncologists may have long-lasting career consequences, especially for those at key stages in their career. The gender gap for promotion to leadership positions may widen further as a result of the pandemic.",
keywords = "COVID-19, gender, inequalities, oncology, survey, woman",
author = "P. Garrido and Adjei, {A. A.} and J. Bajpai and S. Banerjee and Berghoff, {A. S.} and Choo, {S. P.} and E. Felip and Furness, {A. J.S.} and E. Garralda and J. Haanen and A. Letsch and H. Linardou and S. Peters and C. Sessa and J. Tabernero and J. Tsang and Yang, {J. C.H.} and Garassino, {M. C.}",
note = "Funding Information: Writing assistance was provided by Jenny Bryan. Support with the statistical analysis was provided by Cristina Bosetti. This work was supported by the European Society for Medical Oncology (ESMO). PG: Advisory Board: Abbvie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), GlaxoSmithKline, Janssen, Lilly, Merck Sharp & Dohme (MSD), Novartis, Pfizer, Roche, Takeda. Invited Speaker: AstraZeneca, Boehringer Ingelheim, BMS, Janssen, MSD, Novartis, Pfizer, Roche, Takeda. Research funding: Novartis, Janssen, AstraZeneca, Pfizer, Blue-print, Apollomics, Amgen, Array Biopharma. SB: Research grants: AstraZeneca, GlaxoSmithKline (GSK). Honoraria Amgen, Astrazeneca/MSD, GSK, Clovis, Genmab, Immunogen, Merck Serono, Mersana, Pfizer, Roche, Tesaro. ASB: Anna Sophie Berghoff has research support from Daiichi Sankyo (≤€10 000), Roche (>€10 000) and honoraria for lectures, consultation or advisory board participation from Roche, BMS, Merck, Daiichi Sankyo (all <€5000) as well as travel support from Roche, Amgen and AbbVie. EF: Advisory Board: Abbvie, Amgen, AstraZeneca, Bayer, Blue Print Medicines, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Mabxience, MSD, Novartis, Pfizer, Puma Biotechnology, Roche, Sanofi, Genzyme. Invited Speaker: AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, Medscape, MSD, Novartis, Peervoice, Pfizer, Prime Oncology, Roche, Springer, Takeda, Touchime, Cme Outfitters. Research funding: Merck Serono. AJSF: Speaker Fees from BMS, Ipsen, Esai. Consultancy Fees from Sangamo Therapeutics. EG: Speaker: MSD, Roche, Thermo Fisher, Lilly. Advisory Board: Genentech, Roche, Ellipses Pharma, Neomed Therapeutics, Boehringer Ingelheim, Janssen, SeaGen, TFS, Alkermes, Thermo Fisher, BMS, MabDiscovery, Anaveon. Research funding: Novartis, Roche, AstraZeneca, Thermo Fisher, Taiho Oncology. JH: Advisory Board: BMS, Achilles Therapeutics, BioNTech, Immunocore, Gadeta, Ipsen, MSD, Merck Serono, Pfizer, Molecular Partners, Novartis, Neogene Therapeutics, Roche, Sanofi, Third Rock Venture. Stocks/Shares: Neogene Therapeutics. Research Grant: BMS, BioNTech US, MSD, Amgen, Novartis. SP: Consultation/Advisory role: AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, BMS, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Incyte, Janssen, Medscape, MSD, Merck Serono, Merrimack, Novartis, Pharma Mar, Phosphoplatin Therapeutics, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda. Talk in a company's organized public event: AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, F. Hoffmann-La Roche, Illumina, Medscape, MSD, Novartis, Pfizer, Prime, Sanofi, Takeda. Receipt of grants/research supports: (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, BMS, Clovis, F. Hoffmann-La Roche, GSK, Illumina, Lilly, MSD, Merck Serono, Mirati, Novartis, Pfizer, Phoshoplatin Therapeutics. JT: Reports personal financial interest in the form of a scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech, Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics and TheraMyc. Educational Collaboration: Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER). JC-HY: Advisory or consultancy services: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Celgene, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Hansoh Pharmaceuticals, Merck KGaA, MSD, Novartis, Ono Pharmaceuticals, Pfizer, Roche/Genentech, Takeda Oncology, Yuhan Pharmaceuticals. MCG: Reports grants and personal fees from Eli Lilly, personal fees from Boehringer Ingelheim, grants and personal fees from Otsuka Pharma, grants and personal fees from AstraZeneca, grants and personal fees from Novartis, grants and personal fees from BMS, grants and personal fees from Roche, grants and personal fees from Pfizer, grants and personal fees from Celgene, grants and personal fees from Incyte, personal fees from Inivata, personal fees from Takeda, grants from Tiziana Sciences, grants from Clovis, grants from Merck Serono, grants and personal fees from Bayer, grants and personal fees from MSD, grants and personal fees from GlaxoSmithKline S.p.A. grants and personal fees from Sanofi-Aventis, grants and personal fees from Spectrum Pharmaceuticals, grants and personal fees from Blueprint Medicine, personal fees from Seattle Genetics, personal fees from Daiichi Sankyo, grants from United Therapeutics Corporation, grants from Merck KGaA, personal fees from Janssen, non-financial support from MSD, non-financial support from Eli-Lilly, grants from Turning Point, grants from Ipsen, grants from MedImmune, grants from Exelisis, grants from Pfizer, personal fees from Mirati Therapeutics, Regeneron Pharmaceuticals, grants from BMS and Celgene. Non-financial interests: Principal Investigator Keynote 189, MSD - MISP Sunitinib in thymic malignancies (Pfizer), MISP Ramucirumab plus carbo-taxol in thymic malignancies (Eli Lilly), MISP pembrolizumab in low expressors PD-L1(<50%) (MSD), FAME trial metformin and cisplatin pemetrexed in LKB1 loss patients, AIFA grant thymic malignancies. All other authors have declared no conflicts of interest. Funding Information: This work was supported by the European Society for Medical Oncology (ESMO). Publisher Copyright: {\textcopyright} 2021",
year = "2021",
month = jun,
doi = "10.1016/j.esmoop.2021.100131",
language = "English (US)",
volume = "6",
pages = "1--7",
journal = "ESMO Open",
issn = "2059-7029",
publisher = "BMJ Publishing Group",
number = "3",
}